<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Surgery continues to play an important role in the curative treatment of <z:e sem="disease" ids="C0685938" disease_type="Neoplastic Process" abbrv="">gastrointestinal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, considerable progress has been made in chemotherapy and radiotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>In particular, chemotherapy with FOLFIRI and FOLFOX has prolonged survival in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Molecular-targeted agents have also enhanced the effectiveness of chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>However, radical resection offers the potential for a cure and is unsurpassed by any other treatments </plain></SENT>
<SENT sid="5" pm="."><plain>Nonetheless, further improvement in survival is unlikely to be achieved by surgery alone </plain></SENT>
<SENT sid="6" pm="."><plain>Studying how treatment regimens highly effective against unresectable or <z:e sem="disease" ids="C0854750" disease_type="Neoplastic Process" abbrv="">recurrent colorectal cancer</z:e> can be adapted to patients with resectable disease is thus an important issue </plain></SENT>
</text></document>